SHOC2 and cancer: SHOC2 has shown synthetic lethality in KRAS-mutant cancer lines, such as in MiaPaca2 cells treated with MEK inhibitors, which, after initial pathway inhibition, cause pathway rebound and increased RAS GTP loading18.